Sapan Ghai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.
"These attributes position NXP004 for applications in line-extensions for the currently marketed product, or for possible development in future first-to-generic products. The Company has commenced discussions with potential commercialisation partners."
Its in the results, the non-execs are not taking a salary. They will likely receive a payment based on a percentage of any licensing deal done.
Don’t know much about Moderna, what makes you think of them?
Also Julian and Maddie are not taking any salary for the next year.
That’s the first key item jiving. Some posters here were trying to tell us they couldn’t make that statement.
Looks like the additional Oxilio payments were two lots of 50k as predicted.
Nice end to the year, more to come.
Not bad for a dead mid week after Xmas.
Interesting, thanks older.
At least somethings going on anyway.
Like Run-DMC and some posters would say ‘It’s Tricky’
Yep, Merry Xmas everyone.
TRPV2 inhibitor tranilast prevents atrial fibrillation in rat models of pulmonary hypertension
https://www.sciencedirect.com/science/article/abs/pii/S0143416023001513
Not being defensive, just surprised that when people post they can’t explain why they used the words they did.
So what makes you think they are too difficult or complicated?
I stand by saying there’s no reason to not release them now. But legally they don’t have to and previously said by end of Jan.
Quite different from making a somewhat disingenuous statement saying it’s proving tricky.
Why are you saying they are ‘trickier’ FX? What have you heard?
They don’t need to release them until end of January.
Well, clearly not them anyway, whoever it was.
Mainly cash position as you say jiving.
The updated Oxilio deal was prior to period end in September so we will be able to see how much that was.
Still time for the full results to end of September to be released this week.
Maybe I’m being naive but don’t see why not especially now they can mention ‘post period’ payment being received.
Worth noting that Therapeutaix who work closely with NFX are updating their 2020 review article for Drug Discovery Today on “Drug Discovery and Development in IPF” for release in the new year.
Would like to think NXP002 gets a mention.
Will have to wait and see.
Indeed Chab, I enjoy the Schrodingers Cat approach to business here, its both alive and dead at the same time. One day Dan will open the box and we'll find out!
Too many zeros to put on the RNS chab.